The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration.
10.3341/kjo.2016.30.5.369
- Author:
Kyung Hoon SHIN
1
;
Tae Gon LEE
;
Jae Hui KIM
;
Jong Woo KIM
;
Chul Gu KIM
;
Dong Won LEE
;
Jung Il HAN
;
Young Ju LEW
;
Han Joo CHO
Author Information
1. Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, Korea. skhun@kimeye.com
- Publication Type:Original Article
- Keywords:
Aflibercept;
Choroidal hemorrhage;
Macular degeneration;
Retinal hemorrhage
- MeSH:
Choroid Hemorrhage;
Diagnosis;
Follow-Up Studies;
Hemorrhage*;
Humans;
Intravitreal Injections;
Macular Degeneration*;
Retinal Hemorrhage;
Visual Acuity
- From:Korean Journal of Ophthalmology
2016;30(5):369-376
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the efficacy of intravitreal aflibercept monotherapy in submacular hemorrhage (SMH) secondary to wet age-related macular degeneration (AMD). METHODS: This study included 25 eyes in 25 patients with SMH involving the fovea secondary to wet-AMD. All patients were treated with three consecutive monthly intravitreal aflibercept (2.0 mg/0.05 mL) injections, followed by as-needed reinjection. They were followed for at least 6 months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and area of SMH were measured at diagnosis, as well as at 3 and 6 months after treatment initiation. RESULTS: The BCVA significantly improved from 0.79 ± 0.41 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.54 ± 0.41 logMAR at 6 months (p < 0.001). BCVA ≥3 lines and stable vision were observed in 96% of the eyes. The CFT significantly decreased from 560.8 ± 215.3 µm at baseline to 299.8 ± 160.2 µm at 6 months (p < 0.001). The area of SMH significantly decreased from 10.5 ± 7.1 mm² at baseline to 1.8 ± 6.5 mm² at 6 months (p < 0.001). The BCVA, CFT, and area of SMH at baseline, as well as duration of symptoms, all correlated with BCVA at the 6-month follow-up. CONCLUSIONS: Intravitreal injection of aflibercept is an effective treatment option for patients with SMH secondary to wet-AMD; however, there may be limited efficacy in eyes with large SMH area and cases in which treatment is delayed.
